| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 29 | 2022 | 1502 | 4.290 |
Why?
|
| STAT3 Transcription Factor | 8 | 2021 | 90 | 3.120 |
Why?
|
| Neoplastic Stem Cells | 7 | 2020 | 78 | 2.140 |
Why?
|
| Telomerase | 4 | 2017 | 44 | 2.140 |
Why?
|
| Colorectal Neoplasms | 6 | 2017 | 441 | 1.860 |
Why?
|
| Cell Proliferation | 19 | 2022 | 1198 | 1.850 |
Why?
|
| Receptor, erbB-2 | 5 | 2019 | 133 | 1.830 |
Why?
|
| Prostatic Neoplasms | 10 | 2024 | 935 | 1.820 |
Why?
|
| Quercetin | 5 | 2024 | 45 | 1.670 |
Why?
|
| Cell Line, Tumor | 30 | 2022 | 2231 | 1.560 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2022 | 807 | 1.550 |
Why?
|
| Antineoplastic Agents | 12 | 2022 | 803 | 1.480 |
Why?
|
| Signal Transduction | 16 | 2021 | 1908 | 1.350 |
Why?
|
| Neoplasms | 9 | 2022 | 1103 | 1.310 |
Why?
|
| Tea | 4 | 2024 | 45 | 1.210 |
Why?
|
| Transforming Growth Factor beta | 3 | 2021 | 197 | 1.200 |
Why?
|
| STAT1 Transcription Factor | 2 | 2017 | 35 | 1.160 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2019 | 222 | 1.080 |
Why?
|
| Taxoids | 2 | 2016 | 37 | 1.040 |
Why?
|
| NF-kappa B | 4 | 2018 | 339 | 1.020 |
Why?
|
| Humans | 58 | 2024 | 37093 | 0.940 |
Why?
|
| Cell Movement | 8 | 2022 | 571 | 0.930 |
Why?
|
| Phosphorylation | 10 | 2019 | 928 | 0.920 |
Why?
|
| Lignans | 3 | 2024 | 21 | 0.900 |
Why?
|
| Furans | 3 | 2024 | 38 | 0.890 |
Why?
|
| Receptors, Calcitriol | 2 | 2014 | 69 | 0.860 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 70 | 0.850 |
Why?
|
| Interleukin-6 | 3 | 2017 | 153 | 0.820 |
Why?
|
| Curcumin | 3 | 2020 | 74 | 0.800 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2021 | 356 | 0.790 |
Why?
|
| Chemokine CCL2 | 2 | 2020 | 85 | 0.750 |
Why?
|
| Exosomes | 1 | 2022 | 101 | 0.720 |
Why?
|
| Benzamides | 3 | 2017 | 78 | 0.700 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2019 | 58 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2019 | 122 | 0.650 |
Why?
|
| Epigenesis, Genetic | 3 | 2019 | 219 | 0.640 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2020 | 269 | 0.640 |
Why?
|
| Female | 31 | 2022 | 20969 | 0.630 |
Why?
|
| Catechin | 2 | 2015 | 31 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 182 | 0.620 |
Why?
|
| Withanolides | 1 | 2017 | 9 | 0.600 |
Why?
|
| Lactic Acid | 2 | 2022 | 95 | 0.600 |
Why?
|
| Mice | 16 | 2024 | 5913 | 0.600 |
Why?
|
| Chemokine CXCL1 | 1 | 2017 | 15 | 0.590 |
Why?
|
| Estrogen Receptor alpha | 2 | 2015 | 111 | 0.590 |
Why?
|
| Pyrans | 1 | 2017 | 10 | 0.590 |
Why?
|
| Smad4 Protein | 1 | 2017 | 7 | 0.580 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2017 | 42 | 0.580 |
Why?
|
| Drug Synergism | 5 | 2016 | 177 | 0.570 |
Why?
|
| HT29 Cells | 4 | 2017 | 45 | 0.570 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 2014 | 28 | 0.570 |
Why?
|
| Animals | 20 | 2024 | 15081 | 0.560 |
Why?
|
| Mammography | 1 | 2018 | 188 | 0.550 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 52 | 0.550 |
Why?
|
| Glycolysis | 2 | 2022 | 68 | 0.550 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 213 | 0.540 |
Why?
|
| Neoplasm Metastasis | 5 | 2020 | 219 | 0.540 |
Why?
|
| Haplotypes | 2 | 2014 | 182 | 0.540 |
Why?
|
| Flavonoids | 1 | 2016 | 87 | 0.530 |
Why?
|
| Mammary Neoplasms, Animal | 2 | 2020 | 30 | 0.520 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2024 | 54 | 0.510 |
Why?
|
| Gene Expression | 1 | 2018 | 674 | 0.500 |
Why?
|
| Alleles | 2 | 2013 | 321 | 0.500 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 2 | 2020 | 290 | 0.480 |
Why?
|
| Forkhead Transcription Factors | 2 | 2014 | 76 | 0.470 |
Why?
|
| Transcription Factors | 3 | 2020 | 681 | 0.460 |
Why?
|
| MicroRNAs | 6 | 2022 | 426 | 0.450 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 110 | 0.450 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2012 | 12 | 0.430 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 494 | 0.430 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 358 | 0.420 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 502 | 0.420 |
Why?
|
| Phenotype | 4 | 2016 | 689 | 0.410 |
Why?
|
| Immunoprecipitation | 3 | 2017 | 131 | 0.400 |
Why?
|
| Disease Progression | 5 | 2020 | 601 | 0.390 |
Why?
|
| Obesity | 3 | 2020 | 1067 | 0.390 |
Why?
|
| beta Catenin | 3 | 2017 | 48 | 0.390 |
Why?
|
| Neoplasm Invasiveness | 3 | 2018 | 251 | 0.390 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 485 | 0.390 |
Why?
|
| Apoptosis | 9 | 2022 | 1398 | 0.370 |
Why?
|
| DNA Methylation | 2 | 2013 | 325 | 0.370 |
Why?
|
| DNA | 1 | 2013 | 574 | 0.370 |
Why?
|
| Caspase 8 | 1 | 2010 | 32 | 0.360 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 191 | 0.360 |
Why?
|
| Mice, Nude | 5 | 2020 | 337 | 0.360 |
Why?
|
| Serpins | 1 | 2010 | 27 | 0.350 |
Why?
|
| CpG Islands | 1 | 2010 | 97 | 0.350 |
Why?
|
| Models, Biological | 3 | 2022 | 677 | 0.350 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 433 | 0.330 |
Why?
|
| Male | 15 | 2024 | 20025 | 0.320 |
Why?
|
| Tumor Burden | 2 | 2020 | 77 | 0.310 |
Why?
|
| Down-Regulation | 3 | 2015 | 435 | 0.290 |
Why?
|
| Pyrazoles | 2 | 2017 | 85 | 0.290 |
Why?
|
| Middle Aged | 9 | 2018 | 10129 | 0.290 |
Why?
|
| Neovascularization, Pathologic | 4 | 2022 | 127 | 0.280 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2017 | 23 | 0.280 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2019 | 76 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 259 | 0.280 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 448 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2020 | 1039 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 173 | 0.260 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2017 | 161 | 0.260 |
Why?
|
| NIH 3T3 Cells | 2 | 2016 | 61 | 0.250 |
Why?
|
| Disease-Free Survival | 3 | 2022 | 113 | 0.250 |
Why?
|
| Estrogen Receptor beta | 2 | 2015 | 40 | 0.250 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 26 | 0.250 |
Why?
|
| Los Angeles | 4 | 2015 | 380 | 0.250 |
Why?
|
| Ethanol | 2 | 2016 | 192 | 0.240 |
Why?
|
| Up-Regulation | 3 | 2020 | 513 | 0.240 |
Why?
|
| Cohort Studies | 3 | 2021 | 1492 | 0.240 |
Why?
|
| Ligands | 2 | 2023 | 349 | 0.240 |
Why?
|
| Polymerase Chain Reaction | 2 | 2017 | 448 | 0.230 |
Why?
|
| RNA, Small Interfering | 2 | 2018 | 409 | 0.230 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2015 | 23 | 0.230 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2024 | 34 | 0.230 |
Why?
|
| Blotting, Western | 2 | 2017 | 859 | 0.220 |
Why?
|
| Cadherins | 2 | 2014 | 90 | 0.220 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2015 | 864 | 0.220 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2022 | 9 | 0.210 |
Why?
|
| Pancreatic Neoplasms | 1 | 2024 | 111 | 0.210 |
Why?
|
| Community-Based Participatory Research | 3 | 2015 | 317 | 0.210 |
Why?
|
| Drug Design | 1 | 2023 | 162 | 0.210 |
Why?
|
| Muscle Proteins | 1 | 2022 | 51 | 0.200 |
Why?
|
| Connective Tissue Growth Factor | 2 | 2011 | 18 | 0.190 |
Why?
|
| Metformin | 1 | 2022 | 65 | 0.190 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2020 | 95 | 0.190 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2022 | 94 | 0.190 |
Why?
|
| Glucose | 2 | 2022 | 230 | 0.190 |
Why?
|
| Animal Feed | 1 | 2020 | 43 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2020 | 126 | 0.180 |
Why?
|
| Proteins | 1 | 2023 | 369 | 0.180 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 213 | 0.180 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 26 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 623 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1130 | 0.180 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2019 | 67 | 0.180 |
Why?
|
| Genotype | 2 | 2014 | 730 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2021 | 128 | 0.180 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2019 | 11 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2022 | 1371 | 0.170 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 48 | 0.170 |
Why?
|
| Promoter Regions, Genetic | 2 | 2013 | 515 | 0.170 |
Why?
|
| S100 Proteins | 1 | 2019 | 12 | 0.170 |
Why?
|
| Enzyme Activators | 1 | 2019 | 12 | 0.170 |
Why?
|
| Receptors, Estrogen | 2 | 2022 | 156 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 149 | 0.170 |
Why?
|
| Behavioral Research | 1 | 2019 | 39 | 0.160 |
Why?
|
| Inflammation | 2 | 2020 | 618 | 0.160 |
Why?
|
| Mice, SCID | 2 | 2016 | 150 | 0.160 |
Why?
|
| Membrane Glycoproteins | 1 | 2020 | 211 | 0.160 |
Why?
|
| Adipose Tissue | 1 | 2020 | 177 | 0.160 |
Why?
|
| Adult | 6 | 2015 | 11712 | 0.160 |
Why?
|
| Minority Health | 1 | 2019 | 88 | 0.160 |
Why?
|
| Androgens | 2 | 2017 | 89 | 0.160 |
Why?
|
| Nicotine | 1 | 2020 | 257 | 0.160 |
Why?
|
| Phenylthiohydantoin | 1 | 2017 | 2 | 0.160 |
Why?
|
| Androgen Antagonists | 1 | 2017 | 18 | 0.150 |
Why?
|
| Triazines | 1 | 2017 | 20 | 0.150 |
Why?
|
| Chromatin | 1 | 2019 | 169 | 0.150 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2018 | 90 | 0.150 |
Why?
|
| Pyrroles | 1 | 2017 | 55 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2018 | 136 | 0.150 |
Why?
|
| RNA, Messenger | 2 | 2013 | 1207 | 0.150 |
Why?
|
| Gene Expression Profiling | 2 | 2019 | 626 | 0.150 |
Why?
|
| Thiosemicarbazones | 1 | 2017 | 10 | 0.150 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 24 | 0.150 |
Why?
|
| DNA Damage | 1 | 2019 | 352 | 0.150 |
Why?
|
| Hyperinsulinism | 1 | 2016 | 17 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2015 | 753 | 0.140 |
Why?
|
| Ubiquitination | 1 | 2017 | 61 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2017 | 118 | 0.140 |
Why?
|
| Fluorouracil | 1 | 2016 | 34 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2016 | 90 | 0.140 |
Why?
|
| Perception | 2 | 2015 | 195 | 0.130 |
Why?
|
| Survival Rate | 2 | 2015 | 311 | 0.130 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2015 | 19 | 0.130 |
Why?
|
| Receptors, Scavenger | 1 | 2015 | 15 | 0.130 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2015 | 26 | 0.130 |
Why?
|
| Cell Survival | 2 | 2017 | 864 | 0.130 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2015 | 27 | 0.130 |
Why?
|
| Chemokines, CXC | 1 | 2015 | 35 | 0.130 |
Why?
|
| Deoxyglucose | 1 | 2015 | 19 | 0.130 |
Why?
|
| Intracellular Space | 1 | 2015 | 35 | 0.130 |
Why?
|
| Endothelin-1 | 1 | 2015 | 55 | 0.130 |
Why?
|
| Somatomedins | 1 | 2015 | 5 | 0.130 |
Why?
|
| Antibodies | 1 | 2015 | 141 | 0.130 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2015 | 54 | 0.130 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 974 | 0.130 |
Why?
|
| Breast | 1 | 2016 | 135 | 0.120 |
Why?
|
| Insulin Resistance | 1 | 2016 | 184 | 0.120 |
Why?
|
| Early Detection of Cancer | 2 | 2015 | 336 | 0.120 |
Why?
|
| 3T3 Cells | 1 | 2014 | 59 | 0.120 |
Why?
|
| Tamoxifen | 1 | 2015 | 65 | 0.120 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2015 | 113 | 0.120 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2015 | 70 | 0.120 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2014 | 29 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2015 | 196 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 400 | 0.120 |
Why?
|
| Mammary Glands, Animal | 1 | 2014 | 26 | 0.120 |
Why?
|
| Cyclic S-Oxides | 1 | 2013 | 2 | 0.120 |
Why?
|
| Lactation | 1 | 2014 | 40 | 0.120 |
Why?
|
| Loss of Heterozygosity | 1 | 2013 | 19 | 0.120 |
Why?
|
| Body Mass Index | 3 | 2015 | 854 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 67 | 0.120 |
Why?
|
| Minority Groups | 1 | 2019 | 596 | 0.120 |
Why?
|
| RNA-Binding Proteins | 1 | 2015 | 146 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2015 | 173 | 0.110 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2013 | 2 | 0.110 |
Why?
|
| Microsatellite Instability | 1 | 2013 | 43 | 0.110 |
Why?
|
| Carrier Proteins | 1 | 2015 | 305 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2016 | 286 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 169 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2016 | 384 | 0.110 |
Why?
|
| Transfection | 2 | 2010 | 523 | 0.100 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 583 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2012 | 172 | 0.100 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 617 | 0.100 |
Why?
|
| Menopause | 1 | 2011 | 56 | 0.090 |
Why?
|
| Prostate | 2 | 2024 | 154 | 0.090 |
Why?
|
| Vitamin D | 1 | 2013 | 196 | 0.090 |
Why?
|
| Nuclear Proteins | 1 | 2012 | 307 | 0.090 |
Why?
|
| Morpholines | 1 | 2010 | 69 | 0.090 |
Why?
|
| Glioblastoma | 1 | 2010 | 55 | 0.090 |
Why?
|
| Molecular Structure | 2 | 2023 | 492 | 0.090 |
Why?
|
| Chromones | 1 | 2010 | 54 | 0.090 |
Why?
|
| Hydroxamic Acids | 1 | 2010 | 32 | 0.090 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 2721 | 0.090 |
Why?
|
| Chemoprevention | 2 | 2024 | 35 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 767 | 0.090 |
Why?
|
| Risk Factors | 1 | 2018 | 3562 | 0.090 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 111 | 0.090 |
Why?
|
| Enzyme Activation | 1 | 2010 | 444 | 0.080 |
Why?
|
| Acetylation | 2 | 2019 | 98 | 0.080 |
Why?
|
| Prognosis | 2 | 2022 | 739 | 0.080 |
Why?
|
| Comorbidity | 1 | 2011 | 623 | 0.080 |
Why?
|
| Retrospective Studies | 1 | 2014 | 2026 | 0.080 |
Why?
|
| Acetaldehyde | 2 | 2016 | 10 | 0.070 |
Why?
|
| United States | 2 | 2019 | 4223 | 0.070 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 578 | 0.070 |
Why?
|
| Glycosyltransferases | 1 | 2024 | 8 | 0.060 |
Why?
|
| Hormones | 1 | 2022 | 55 | 0.050 |
Why?
|
| Proteome | 1 | 2024 | 144 | 0.050 |
Why?
|
| Interferons | 1 | 2022 | 34 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2022 | 19 | 0.050 |
Why?
|
| Mecamylamine | 1 | 2020 | 15 | 0.050 |
Why?
|
| Risk-Taking | 2 | 2015 | 451 | 0.050 |
Why?
|
| Interferon-alpha | 1 | 2021 | 43 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2024 | 933 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 122 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2015 | 1067 | 0.050 |
Why?
|
| Sirolimus | 1 | 2020 | 60 | 0.050 |
Why?
|
| Health Behavior | 2 | 2015 | 537 | 0.050 |
Why?
|
| Imidazoles | 1 | 2020 | 126 | 0.050 |
Why?
|
| Hypoglycemic Agents | 1 | 2022 | 160 | 0.040 |
Why?
|
| Pyridines | 1 | 2020 | 116 | 0.040 |
Why?
|
| Adipokines | 1 | 2020 | 24 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2024 | 517 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 250 | 0.040 |
Why?
|
| Adipocytes | 1 | 2020 | 58 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 224 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 132 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2021 | 259 | 0.040 |
Why?
|
| Epidermal Growth Factor | 1 | 2019 | 68 | 0.040 |
Why?
|
| Research Support as Topic | 1 | 2019 | 80 | 0.040 |
Why?
|
| Base Sequence | 1 | 2020 | 997 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2020 | 661 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 2379 | 0.040 |
Why?
|
| Hela Cells | 1 | 2019 | 366 | 0.040 |
Why?
|
| Research Personnel | 1 | 2019 | 155 | 0.040 |
Why?
|
| Cultural Diversity | 1 | 2019 | 169 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 55 | 0.040 |
Why?
|
| Histones | 1 | 2019 | 190 | 0.040 |
Why?
|
| Nitriles | 1 | 2017 | 69 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2019 | 229 | 0.040 |
Why?
|
| Cytokines | 1 | 2020 | 602 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 461 | 0.030 |
Why?
|
| Estrogens | 1 | 2016 | 202 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2020 | 938 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 808 | 0.030 |
Why?
|
| Young Adult | 2 | 2015 | 4268 | 0.030 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2013 | 12 | 0.030 |
Why?
|
| Adolescent | 2 | 2015 | 5363 | 0.030 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 1 | 2013 | 2 | 0.030 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2013 | 9 | 0.030 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2013 | 48 | 0.030 |
Why?
|
| Aged | 2 | 2015 | 6741 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2019 | 642 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2013 | 166 | 0.030 |
Why?
|
| Cell Line | 1 | 2016 | 1354 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 152 | 0.030 |
Why?
|
| Cell Death | 1 | 2013 | 267 | 0.030 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 277 | 0.020 |
Why?
|
| Genomics | 1 | 2013 | 223 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 41 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2010 | 45 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 893 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1015 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2011 | 212 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 172 | 0.020 |
Why?
|
| Mutation | 1 | 2011 | 1095 | 0.020 |
Why?
|